Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Beyond Air, Inc. (NASDAQ: XAIR) will report its financial results for the second fiscal quarter ended September 30, 2020, on November 11, 2020, followed by a conference call at 4:30 PM ET. The company focuses on developing inhaled nitric oxide for respiratory conditions and gaseous NO for treating tumors. Its product, LungFit™, can deliver precise NO dosage continuously or at fixed intervals, with ongoing clinical trials targeting severe lung infections, including SARS-CoV-2. For more information, visit www.beyondair.net.
Beyond Air, Inc. (NASDAQ: XAIR) announced plans to initiate a clinical study to evaluate the safety and efficacy of the LungFit™ system using inhaled Nitric Oxide (NO) for hospitalized adults with acute viral pneumonia, including SARS-CoV-2 infections. The multi-center trial in Israel aims to enroll 90 patients, comparing NO treatment combined with standard supportive care against supportive care alone. The LungFit™ system generates NO from ambient air, providing potential advantages in treating respiratory conditions.
Beyond Air (NASDAQ: XAIR) announced promising preclinical data indicating that high concentrations of gaseous nitric oxide (gNO) administered directly to solid tumors may induce a systemic anti-tumor immune response. Key findings from studies on colon and breast cancer-bearing mice indicated that 100% of naïve mice had tumor uptake, whereas 27% and 0% of treated mice showed uptake, suggesting a dose-dependent effect. The company aims to further explore gNO's clinical potential, with a first in human study anticipated. This innovative approach could represent a significant shift in cancer treatment.
Beyond Air, Inc. (NASDAQ: XAIR) recently presented significant in vitro data at the CHEST Annual Meeting 2020, indicating that its LungFit™ system may serve as a potential treatment for human coronavirus infections. The data revealed a 96% reduction in viral infectivity and over 75% improvement in host cell viability after exposure to nitric oxide (NO) at 250 ppm. Additionally, intermittent dosing with 150-250 ppm NO showed promising results, including complete inhibition of infectivity. Beyond Air aims to advance LungFit™ for clinical trials addressing severe lung infections, including COVID-19.
Beyond Air (NASDAQ: XAIR) has shared promising data on its bronchiolitis program during the CHEST Annual Meeting 2020. The pilot study, involving 87 infants, found that inhaled nitric oxide (NO) at 150 ppm significantly outperformed standard supportive therapy and 85 ppm NO in reducing hospital stay and improving oxygen saturation. All treatment groups exhibited similar safety profiles, with no serious drug-related adverse events reported. CEO Steve Lisi expressed optimism about advancing the LungFit™ system towards a definitive study, underscoring the potential of NO as a therapeutic agent for respiratory infections.
Beyond Air, Inc. (NASDAQ: XAIR) announced promising preclinical data suggesting that its gaseous nitric oxide (gNO) treatment can effectively target lung cancer. In in vitro tests, gNO reduced viability of LLC1 lung cancer cells in a dose-dependent manner. Additionally, in vivo studies showed that 100% of gNO-treated mice rejected a subsequent tumor challenge, while all control mice accepted the tumor challenge. The results were presented at the IASLC North America Conference on Lung Cancer 2020, supporting gNO's potential as a treatment for both primary and metastatic lung cancer.
Beyond Air, Inc. (NASDAQ: XAIR) announced that Chairman and CEO Steven Lisi will attend the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit from September 21-23, 2020. Lisi's presentation is scheduled for September 22 at 10:00 a.m. EDT, with a live webcast available via Oppenheimer.
Beyond Air specializes in developing inhaled nitric oxide therapies for respiratory conditions. Their LungFit™ system generates nitric oxide from ambient air for treating various pulmonary diseases, with ongoing clinical trials targeting severe lung infections.
Beyond Air, Inc. (NASDAQ: XAIR) announced acceptance of two e-posters for the CHEST 2020 Annual Meeting from October 18th to 21st. The first study evaluates two doses of inhaled nitric oxide for bronchiolitis, led by Aviv Goldbart, MD. The second highlights nitric oxide's potential as an anti-coronavirus agent, authored by Matan Goldshtein, PhD. Beyond Air's LungFit™ system is in clinical trials targeting severe lung infections, including COVID-19. For more details, the e-posters will be available on the CHEST 2020 website and Beyond Air's site.
Beyond Air, Inc. (NASDAQ: XAIR) announced the acceptance of its e-poster presentation at the IASLC North America Conference on Lung Cancer 2020, scheduled for October 16-17, 2020. The presentation, titled New Class of Cancer Vaccination Using a Single Injection of Nitric Oxide Shows Promising Results in a Lung Cancer Mouse Model, will be led by Hila Confino, PhD. This highlights the company's focus on innovative treatments using inhaled nitric oxide for respiratory conditions and solid tumors. The final e-poster and audio presentation will be available on the NACLC website and Beyond Air's website.
Beyond Air, Inc. (NASDAQ: XAIR) reported results from a compassionate use case study of inhaled nitric oxide (NO) for treating pulmonary Mycobacterium abscessus disease. Conducted at the National Heart, Lung, and Blood Institute, the study involved a 24-year-old cystic fibrosis patient with treatment-resistant M. abscessus. After a 21-day treatment regimen, the patient experienced improved respiratory symptoms and quality of life, although no significant change in bacterial cultures was noted. Results indicate a heterogeneous response to NO, suggesting longer treatments may be necessary for resistant strains. A 12-week study is planned for later this year.